Bausch Health Companies I... (BHC)
| Bid | 6.65 |
| Market Cap | 2.47B |
| Revenue (ttm) | 9.83B |
| Net Income (ttm) | 98M |
| EPS (ttm) | 0.26 |
| PE Ratio (ttm) | 25.71 |
| Forward PE | 1.59 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 6.83 |
| Volume | 1,332,151 |
| Avg. Volume (20D) | 2,611,919 |
| Open | 6.62 |
| Previous Close | 6.55 |
| Day's Range | 6.60 - 6.80 |
| 52-Week Range | 4.25 - 9.85 |
| Beta | 0.43 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for BHC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAnalysts project revenue of ... Unlock content with Pro Subscription
4 days ago · accessnewswire.com
Bausch Health to Announce Third Quarter 2025 Results on October 29LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025....
3 weeks ago · seekingalpha.com
Bausch Health: Repricing Continues As Deleveraging Gains TractionBausch Health remains a Buy as the market overstates debt and patent risks, while the business shows stable cash generation and operational momentum. Q2 results confirmed growth in core segments, impr...
1 month ago · accessnewswire.com
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ:DRRX) t...
